These findings were corroborated in a study of 61 TP53-mutated MDS/AML patients treated with the HMA azacitidine +/− the anti-PDL1 antibody durvalumab in the FUSION clinical trial. The gene discussed is TP53; the disease is acute myeloid leukemia.